A first combination case of 21-hydroxilase deficiency and CHARGE syndrome confirmed by genetic analysis

Miyuki Kitamura¹, Yuko Katoh-Fukui², Maki Fukami², ShuichiYatsuga¹, Takako Matsumoto¹
Junko Nishioka¹, Yasutoshi Koga¹
1. Department of Pediatrics and Child Health, Kurume University School of Medicine
2. Department of Molecular Endocrinology, National Research Institute for Child Health and Development

Introduction

21-hydroxilase deficiency (21OHD)
autosomal recessive inheritance
Disease gene : CYP21A2

Cause of over 90% Congenital Adrenal Hyperplasia cases
- Adrenal crisis due to salt wasting form
- Ambiguous genitalia (female)
- Penile enlargement (male)
- Hypert pigmentation
- Postnatal virilization
- Linear growth

CHARGE syndrome (CS)
autosomal dominant inheritance
Disease gene : CHD7

Major criteria
- Coloboma
- Choanal atresia/stenosis
- Hypoplasia/aplasia of semicircular canal
Minor criteria
- Rhombencephalic dysfunction
- Hypothalamo-hypophysial dysfunction
- Malformation of the internal external ear
- Malformation of mediastinal organs (heart, oesophagus)
- Intellectual disability
- Typical: 3 major or 2 major and 2 minor, Partial: 2 major and 1 minor
- Atypical: 2 major but no minor, or 1 major and 2 minor

Case Report: 7 year-old boy

[Clinical course]
- No problems in perinatal period, 37 weeks of gestational age.
- No consanguinity of parents.
- His brother suffered from 21OHD (simple virilizing form)
- At birth, having cleft lip and palate, ventricular heart sepal defect, patent ductus arteriosus.
- No symptoms of 21OHD.
- No pigmentation of scrotum nor penile enlargement.
- At the age of 7 days, developing heart failure due to VSD. Diuretic drug started.
- At the age of 9 days, showing electrolyte abnormality, hypoglycemia and high values of 17-hydroxyprogesterone:18.3 ng/mL (<3.5 ng/mL).

Clinically diagnosed with 21OHD and treated with fludrocortisone acetate and hydrocortisone.
- Genetic analysis: VS2-13A/C>G/I172N in CYP21A2. The same mutation of his brother.
- When he was referred to our hospital at the age of 3 months, he had various complications added to 21OHD symptoms.

[Summary of Complications]

Why does he show such various complications?
Not common features of 21OHD.

Genetic analysis of CHD7 at age of 5 years

Discussion

Genotype-phenotype correlation in 21OHD
Genotype-phenotype in 21OHD has been known in previous reports.3,4,5 Generally, IVS2-13A/C>G mutation appears as 50% of salt wasting form and I172N mutation mainly appears as simple virilization form. Although our patient was salt wasting form, his brother was simple virilization. This difference of phenotype may depend on residual enzyme activity.

His external genitalia had weak virilization. In our case, may be strongly influenced by CS than 21OHD.

Why does his external genitalia have weak virilization; androgen excess in 21OHD v.s. androgen deficiency in CS?

Premise: In 21OHD, adrenal androgen excess induces acceleration of virilization.

In CS, hypogonadotropic hypogonadism induces external genital hypoplasia.

Hypothesis
1. In 21OHD, an excess amount of secreted adrenal androgen during fetal period may be less than the required amount to maintain virilization during latter fetal period.
2. The role of CHD7 is still uncertain. CHD7 may have some specific role in the formation of external genitalia during fetal period.

Conclusion

We report a first combination case of 21OHD and CS confirmed by genetic analysis. We consider that this case occured accidently. When the patients have atypical symptoms, we should consider that they have another disease additional to the primary disease.

An interesting point in our case is that his external genitalia had weak virilization. However, the cause is not clear. When a female case will be reported in the future, a clinical feature of a combination case with 21OHD and CS may be more clear.

References

1) Verloes A. Am J Med Genet A. 2005
3) Tajima T et al, J Clin Invest. 1993
5) New MI et al, Proc Natl Acad Sci USA. 2013
6) The Japanese Society of Pediatric Endocrinology websites diagnosis and treatment in CDD

Adrenals and HPAs Axis
Miyuki Kitamura

Poster online at: